compounded glp 1 ending Is the GLP-1 compounding boom over? Yes You Can Medical |
Description
Combining bimagrumab with semaglutide led to 22% weight loss, with 93% of that loss coming from fat and minimal lean mass reduction
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist
GLP-1 drugs such as semaglutide are reshaping treatment of obesity, diabetes and cardiovascular disease with broader physiological effects now emerging.
Understand the impact of GLP-1 medications on mental health and how they can affect your mood.
Despite these findings, a clear link has yet to be established, and much of the evidence remains inconsistent
Read the article to know more.
